New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
09:07 EDTOXGNOxigene presents encouraging OXi4503 preclinical and clinical data
Oxigene announced that investigators at the University of Florida presented encouraging clinical data using Oxigene's vascular disrupting agent, or VDA, OXi4503, in patients with acute myelogenous leukemia, or AML, at the annual meeting of the American Society of Hematology in Atlanta, Georgia. The data showed responses and a manageable safety profile in this first-in-man trial of a VDA in AML. Overall response was 2/5, or 40%, with 1 patient achieving a marrow complete remission, or mCR, and 1 patient achieving a partial remission. The median number of cycles was 1, in a range of 1-6. Three of 5 subjects discontinued the study due to AML progression and one due to pneumonia. One patient with AML treated with 5 mg/m2 OXi4503 has received 6 months of treatment and continues to receive weekly infusions.
News For OXGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 20, 2015
19:02 EDTOXGNOn The Fly: After Hours Movers
UP AFTER EARNINGS: (CRM), up 6.6%... Williams-Sonoma (WSM), up 4%. ALSO HIGHER: CTPartners (CTP), up 42% after agreeing to exclusive negotiations to be acquired by DHR International. DOWN AFTER EARNINGS: Xunlei (XNET), down 14.9%... NetApp (NTAP), down 8%... Open Text (OTEX), down 7.7%.... Rexnord (RXN), down 7.1%... Synopsys (SNPS), down 1.5%... Youku Tudou (YOKU), down 1.2%. ALSO LOWER: Wave Systems (WAVX), down 8.5% after filing to sell Class A common stock and warrants... OXiGENE (OXGN), down 5.1% after filing mixed securities shelf.
16:29 EDTOXGNOXiGENE files $75M mixed securities shelf
May 12, 2015
16:02 EDTOXGNOXiGENE appoints Bill Schwieterman as CEO
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use